A new study released in Lancet Oncology showed that abnormal levels of female hormones in the bloodstream may be why women with BRCA1 or BRCA2 mutations are at a higher risk for breast and ovarian cancer and not other cancers. UCL Department of Women’s Cancer completed the study that found different levels of the female hormones oestradiol and progesterone in women with BRCA1 or BRCA2.
Related Topics
Researchers Discover Potential Therapeutic Targets for Low-Grade Serous Ovarian Cancer
Scientists have identified sixteen potential therapeutic targets in low-grade serous ovarian cancer by studying proteins at the molecular level, with results published on August 11, 2025, in the journal Cancer … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical Cancer Patients
This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We … Continued
FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with … Continued